<DOC>
	<DOCNO>NCT02480166</DOCNO>
	<brief_summary>The primary objective study describe efficacy : 1 . 8-week treatment SOF/LED treatment-naïve , non-cirrhotic , HCV genotype 6 2 . 12-week treatment SOF/LED HCV-6 population</brief_summary>
	<brief_title>Comparative Efficacy Fixed-dose Combination Sofosbuvir + Ledipasvir , 8 vs. 12 Weeks Chronic Hepatitis C Genotype 6</brief_title>
	<detailed_description>The secondary objective study describe safety , persistency , tolerability SOF/LED patient HCV-6 .</detailed_description>
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis C</mesh_term>
	<mesh_term>Hepatitis , Chronic</mesh_term>
	<mesh_term>Hepatitis C , Chronic</mesh_term>
	<mesh_term>Sofosbuvir</mesh_term>
	<mesh_term>Ledipasvir</mesh_term>
	<mesh_term>Ledipasvir , sofosbuvir drug combination</mesh_term>
	<criteria>1 . Male female , age ≥18 year 2 . HCV genotype 6 indeterminate later assess Screening confirm genotype 6 3 . Selected start treatment treat provider 4 . Willing able provide inform consent 5 . Able comply dose instruction study drug administration able complete study schedule assessment 6 . Females childbearing potential must negative serum pregnancy test Screening negative pregnancy test Baseline 7 . Male subject female subject childbearing potential engage heterosexual intercourse must agree use protocol specify method ( ) contraception 8 . Lactating female must agree discontinue nursing study drug administer 1 . Previous recipient liver transplant 2 . Coinfection human immunodeficiency virus ( HIV ) hepatitis B ( HBV )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>hepatitis C , genotype 6</keyword>
</DOC>